Andrea Eleazar, MHS

The FDA clears KLN-1010, a groundbreaking in vivo gene therapy for relapsed multiple myeloma, enhancing CAR-T treatment accessibility and efficacy.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

A new trial explores the effectiveness of calderasib combined with pembrolizumab for advanced lung cancer patients with the KRAS G12C mutation.

A recent study reveals CAR T-cell therapy patients in Europe experience quality of life comparable to the general population, yet face ongoing physical and mental challenges.

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options.

A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent high-grade bladder cancer, emphasizing patient-centered care.

Discover groundbreaking advancements in glioblastoma treatment, including FDA approvals and innovative therapies reshaping neuro-oncology in 2025.

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients.

Melanoma treatment advances with lifileucel's promising efficacy, regulatory updates, and innovative therapies, shaping a hopeful landscape for patients.

A new study reveals that common chronic medications do not impact the effectiveness of immune checkpoint inhibitors in metastatic lung cancer treatment.

A new study reveals FOLFIRINOX chemotherapy is feasible for select elderly patients with pancreatic cancer, highlighting safety and survival outcomes.

A phase 2 trial reveals elraglusib shows potential benefits in select patients with recurrent salivary gland carcinomas despite missing primary response goals.

New trial results reveal nivolumab plus relatlimab fails to improve recurrence-free survival in resected stage III-IV melanoma, prompting further research.

Duvelisib is now a recommended treatment for cutaneous T-cell lymphoma, highlighting its evolving role in oncology amidst safety concerns.

The FDA fast-tracks BGB-B2033, a promising bispecific antibody, for advanced hepatocellular carcinoma, enhancing treatment options for patients.

Pelareorep shows promising results in treating KRAS-mutant metastatic colorectal cancer, achieving a 33% response rate and improved survival outcomes.

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

FDA fast-tracks muzastotug and pembrolizumab for metastatic colorectal cancer, showcasing promising efficacy and safety in early studies.

FDA grants a priority voucher for Tec-Dara, showcasing significant survival benefits in relapsed/refractory multiple myeloma, enhancing treatment options.

Inaregacestat shows promising results in treating desmoid tumors, significantly improving progression-free survival and reducing tumor volume in recent trials.

New data from the TRIFOUR trial show that nadunolimab plus chemotherapy offers no significant survival benefit in metastatic triple-negative breast cancer.

New research shows less invasive surgical options for breast cancer staging are as effective as traditional methods, enhancing patient quality of life.

Aromatase inhibitors enhance disease-free survival in HR+/HER2+ early breast cancer, outperforming SERMs without compromising overall survival, according to ALTTO trial findings.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

Cevostamab shows promising efficacy and manageable safety in treating relapsed/refractory multiple myeloma, offering a convenient subcutaneous administration option.

A recent study reveals high rates of metastatic recurrence in adolescent and young adult cancer patients, emphasizing the need for tailored survivorship care.